During the past decade, Richmond Behavioral Associates conducted 75 clinical trials. In the 10-year time frame, 75 clinical trials started and 41 clinical trials were completed, i.e. on average, 54.7% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 19 clinical trials were completed. i.e. 54.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Richmond Behavioral Associates" #1 sponsor was "Sunovion" with 12 trials, followed by "Otsuka Pharmaceutical Development & Commercialization, Inc." with 11 trials sponsored, "Shire" with 9 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored and "Cephalon" with 8 trials sponsored. Other sponsors include 73 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Richmond Behavioral Associates" #1 collaborator was "Otsuka America Pharmaceutical" with 4 trials as a collaborator, "National Institute on Aging (NIA)" with 3 trials as a collaborator, "Alzheimer's Association" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator and "Alzheimer's Drug Discovery Foundation" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Richmond Behavioral Associates" are "Major Depressive Disorder" (16 trials), "Alzheimer Disease" (15 trials), "Alzheimer's Disease" (12 trials), "Schizophrenia" (12 trials) and "Depressive Disorder, Major" (7 trials). Many other conditions were trialed in "Richmond Behavioral Associates" in a lesser frequency.

Most popular intervention types in "Richmond Behavioral Associates" are "Drug" (114 trials), "Other" (6 trials), "Biological" (5 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (75 trials), "Lurasidone" (5 trials), "Gantenerumab" (4 trials), "Rapastinel" (4 trials) and "Armodafinil" (3 trials). Other intervention names were less common.

The vast majority of trials in "Richmond Behavioral Associates" are 121 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Richmond Behavioral Associates". undefined are not yet recruiting, 20 are recruiting, 10 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 69 completed trials in Richmond Behavioral Associates, 1 suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Richmond Behavioral Associates, 3 "Phase 1" clinical trials were conducted, 47 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 2 trials that are defined as “Not Applicable".